News & Updates
Filter by Specialty:
Investigational nasal spray for dry eye disease scores high in phase II trial
The single-dose nicotinic acetylcholine receptor agonist OC-02, administered as an aqueous nasal spray, helps increase tear production and improve eye dryness in patients with dry eye disease (DED), according to data from the phase II PEARL trial.
Investigational nasal spray for dry eye disease scores high in phase II trial
16 Aug 2022
PLWH at a disadvantage in receiving statin therapy for ASCVD risk reduction
People living with HIV (PLWH) are less likely to receive appropriate statin therapy for the prevention of atherosclerotic cardiovascular disease (ASCVD), a study has found.
PLWH at a disadvantage in receiving statin therapy for ASCVD risk reduction
16 Aug 2022
How effective is ensovibep in hospitalized adults with COVID-19?
Hospitalized patients with COVID-19 who are receiving remdesivir and other standard care show no improvements in clinical outcomes with the addition of ensovibep, according to the results of a study.
How effective is ensovibep in hospitalized adults with COVID-19?
16 Aug 2022
Does TB influence viral suppression in HIV patients on DTG-based therapy?
Incident tuberculosis (TB) appears to be a risk factor for virologic non-suppression (ie, viral load of >1,000 copies/mL) in HIV patients who have transitioned to dolutegravir (DTG)-based therapy with recycled NRTIs*, according to a retrospective subanalysis of the VISEND study.
Does TB influence viral suppression in HIV patients on DTG-based therapy?
16 Aug 2022
Survival benefit with postchemoradiation immunotherapy affirmed
Starting immunotherapy after chemotherapy and radiation for unresectable stage III nonsmall cell lung cancer (NSCLC) prolongs overall survival, regardless of patient age, health, and socioeconomic status, according to a large US study.
Survival benefit with postchemoradiation immunotherapy affirmed
15 Aug 2022
Subgroup analyses boost masupirdine potential for AD
Post hoc data from a phase II study presented at AAIC 2022 continue to demonstrate the potential of masupirdine (SUVN-502), a selective 5-HT6 receptor antagonist, as a treatment alternative for the management of neuropsychiatric and cognitive symptoms of Alzheimer’s disease (AD).